A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
for Gastrointestinal Neoplasms
36 locations incl. Phoenix
Sponsor: GlaxoSmithKline
Sex: All·Age: 18+
Code: NCT07218926·Phase 3·Recruiting